文献速递生殖医学

一项多中心随机对照试验随访的产科与围产期结局:延时胚胎监测研究

Obstetric and perinatal outcomes from the follow-up of a multicentre randomized controlled trial investigating time-lapse embryo monitoring.
PubMed 文献 · Hum Reprod · 2026-01-01

本研究对参与SelecTIMO多中心随机对照试验的1731例IVF/ICSI患者进行随访,比较延时培养箱中无中断培养联合或不联合机器学习胚胎选择算法与中断培养联合形态学选择的产科和围产期结局;结果显示三组严重妊娠并发症、早产、出生体重等安全性结局相当。

要点

  • 延时培养箱无中断培养联合或不联合机器学习胚胎选择,与中断培养联合形态学选择相比,产科和围产期结局相当。
  • 三组严重妊娠并发症比例相当:TLE vs CON的RRadj为0.95(95%CI 0.65-1.40),TLR vs CON的RRadj为1.03(95%CI 0.70-1.50)。
  • 三组单胎出生体重均值(标准差)分别为3413(588)g、3412(588)g、3377(578)g,差异无统计学意义。

核心结论

  • 无中断延时培养联合或不联合基于机器学习的胚胎选择,在产科和围产期风险方面与中断培养联合常规形态学选择相比,可被视为安全。

研究设计与样本

  • 研究为多中心随机对照试验(SelecTIMO试验)的随访,纳入1731例计划行第3天单胚胎移植的IVF/ICSI患者,随机分为三组:TLE组(基于市售第3天TLM算法联合形态学选择胚胎,无中断培养)、TLR组(常规形态学选择胚胎,无中断培养)、CON组(常规形态学选择胚胎,中断培养)。
  • 随访登记与初始取卵周期相关的鲜胚和冻胚移植后以及1年内自然受孕的所有妊娠的产科和围产期数据,主要安全性结局为严重妊娠并发症和出生体重。

主要发现

  • 随访期间共827例女性分娩单胎(TLE=275,TLR=278,CON=274;P=0.99)。
  • 827例单胎分娩中,497例(60%)来自鲜胚移植,294例(36%)来自冻胚移植,36例(4%)为自然受孕,各组比例相似。
  • 严重妊娠并发症比例在三组间相当:TLE vs CON的RRadj为0.95(95%CI 0.65-1.40),TLR vs CON的RRadj为1.03(95%CI 0.70-1.50);P=0.89。
  • 出生时孕周均值(标准差)分别为39.4(1.9)周、39.5(1.5)周、39.3(1.9)周;未发现组间早产和极早产差异的证据。
  • 出生体重均值(标准差)分别为3413(588)g、3412(588)g、3377(578)g(TLE vs CON:MD 34,95%CI -62至129;TLR vs CON:MD 32,95%CI -635至120;P=0.70);未观察到低出生体重和极低出生体重儿的显著差异。

临床怎么用

  • 作者认为,与中断胚胎培养和常规形态学选择相比,无中断延时培养联合或不联合基于机器学习的胚胎选择在产科和围产期风险方面可被视为安全。

局限性

  • 本研究仅报告了一种类型延时培养箱的安全性结局,但目前有更多系统可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does uninterrupted culture in a time-lapse incubator with or without a commercially available machine learning embryo selection algorithm result in comparable obstetric and perinatal outcomes as interrupted culture and morphological embryo selection? SUMMARY ANSWER: The application of uninterrupted culture in a time-lapse incubator with and without the use of an embryo selection algorithm is comparable to interrupted embryo culture and morphological embryo selection in terms of obstetric and perinatal results. WHAT IS KNOWN ALREADY: There is very limited evidence regarding the safety of time-lapse monitoring (TLM) from prospective randomized controlled trials (RCT). Recent RCTs have demonstrated that the application of TLM does not increase (cumulative) live birth rates or shorten the time to pregnancy within 1 year. Although most studies only report pregnancy rates, the safety of this commonly used method is also relevant for decision-making. STUDY DESIGN, SIZE, DURATION: The obstetric and perinatal outcomes of patients scheduled for Day 3 single embryo transfer who participated in a multicentre RCT on TLM were studied (SelecTIMO trial). Three groups were compared: (i) TLE: embryo selection based on a commercially available Day 3 TLM algorithm, used adjunctively with morphology, and uninterrupted culture. (ii) TLR: routine morphological embryo selection and uninterrupted culture. (iii) CON: routine morphological embryo selection and interrupted culture. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 1731 IVF/ICSI patients undergoing their first, second, or third oocyte retrieval cycle were randomized. Obstetric and perinatal data were registered for all pregnancies occurring after fresh and frozen embryo transfers associated with the initial oocyte retrieval cycle as well as natural conceptions within 1 year. Serious pregnancy complications and birth weight were considered main safety outcomes. Mean differences (MD) and age-adjusted relative risks (RRadj) and mean differences with 95% CI were calculated for TLE and TLR versus CON. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 827 women gave birth to a singleton during the follow-up period (TLE = 275, TLR = 278, CON = 274; P = 0.99). Of the 827 women who gave birth to a singleton, 497 deliveries originated from a fresh embryo transfer (60%), 294 from a frozen embryo transfer (36%), and 36 women conceived naturally (4%), with similar proportions in each study group. The proportion of women with serious pregnancy complications was comparable across the three groups (TLE vs CON: RRadj 0.95, 95% CI 0.65-1.40 and TLR vs CON: RRadj 1.03, 95% CI 0.70-1.50; P = 0.89). Mean (SD) gestational age at birth was 39.4 (1.9) weeks, 39.5 (1.5) weeks, and 39.3 (1.9) weeks, respectively. We found no evidence of differences in preterm and very preterm births between groups. Mean (SD) weight at birth was 3413 (588) g, 3412 (588) g, and 3377 (578) g, respectively (TLE vs CON: MD 34, 95% CI -62 to 129 and TLR vs CON: MD 32, 95% CI -635 to 120; P = 0.70). We did not observe substantial differences in babies with low and very low birth weight. Health problems immediately after delivery were reported for eight babies in the TLE group, 12 in the TLR group, and 11 in the CON group. Major congenital malformations occurred in four children in the TLE group, four in the TLR group, and seven in the CON group. Minor congenital malformations occurred in five children in the TLE group, three in the TLR group, and five in the CON group. LIMITATIONS, REASONS FOR CAUTION: This study reports safety outcomes for one type of time-lapse incubator, however, more systems are currently available. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that uninterrupted time-lapse culture with and without embryo selection based on machine learning can be regarded as safe compared to interrupted embryo culture and routine morphological selection in terms of obstetric and perinatal risks. STUDY FUNDING/COMPETING INTEREST(S): The authors received a grant from the Netherlands Organisation for Health Research and Development (ZonMw) for the execution of the SelecTIMO study (Health Care Efficiency Research programme grant 843001602). Merck (Germany and The Netherlands) supplied the six time-lapse incubators, funded the laboratory adjustments, and provided technical support and training to laboratory personnel before and during the study. D.C.K. received the Fertility Society of Australia exchange award. The following declarations of interest were made outside of the submitted work: F.B. reports additional financial support for the LUMO trial from Besins Healthcare Monaco, fellowship grants for ongoing basic research from Merck, consulting fees and payment or honoraria from Merck, Besins, and Ferring, and is member of the DSMB of the POISE study UK. J.M.J.S. has received grants or contracts from Ferring BV and Merck (payments to ETZ in both cases); consulting fees for an advisory board from Ferring BV; speakers fee from Merck BV; and support for conference attendance from Ferring BV, Merck, and Goodlife. M.v.W. is Senior Editor of Cochrane and Editor-in-Chief of Human Reproduction Update. C.B.L. reports a speakers honorarium from Organon (The Netherlands) and was Editor In Chief for Human Reproduction at the time of submitting this manuscript. TRIAL REGISTRATION NUMBER: NTR5423: ICTRP Search Portal (who.int).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kieslinger DC, Vergouw CG, von Estorff F, et al. Obstetric and perinatal outcomes from the follow-up of a multicentre randomized controlled trial investigating time-lapse embryo monitoring. Hum Reprod. 2026. PMID: 41139424. doi:10.1093/humrep/deaf197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。